Brokerages Set Affimed (NASDAQ:AFMD) Target Price at $45.00

Shares of Affimed (NASDAQ:AFMD) have been assigned an average recommendation of “Buy” from the five research firms that are covering the firm, MarketBeat reports. Five investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $45.00.

Several equities analysts recently commented on AFMD shares. Cantor Fitzgerald restated an “overweight” rating on shares of Affimed in a research report on Monday, April 1st. Wells Fargo & Company reduced their target price on shares of Affimed from $30.00 to $25.00 and set an “overweight” rating on the stock in a research note on Monday, April 1st. Finally, HC Wainwright increased their target price on shares of Affimed to $10.00 and gave the stock a “buy” rating in a research report on Monday, April 1st.

Affimed Price Performance

Shares of AFMD opened at $5.23 on Monday. The company has a quick ratio of 3.23, a current ratio of 3.25 and a debt-to-equity ratio of 0.11. The company has a 50-day moving average price of $5.42 and a two-hundred day moving average price of $5.09. The stock has a market cap of $79.65 million, a price-to-earnings ratio of -0.62 and a beta of 2.05. Affimed has a 12 month low of $2.23 and a 12 month high of $11.10.

Institutional Trading of Affimed

Large investors have recently made changes to their positions in the business. EWA LLC acquired a new position in Affimed during the 4th quarter worth about $89,000. abrdn plc bought a new position in shares of Affimed in the fourth quarter worth about $130,000. Vestal Point Capital LP bought a new position in shares of Affimed in the fourth quarter worth about $341,000. Finally, BNP Paribas Financial Markets grew its stake in shares of Affimed by 39.9% during the fourth quarter. BNP Paribas Financial Markets now owns 571,975 shares of the biopharmaceutical company’s stock valued at $357,000 after purchasing an additional 163,162 shares during the last quarter. Institutional investors own 30.82% of the company’s stock.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.